<p>/PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) 和 MS Pharma 联合宣布，他们已签署一项独家许可和供应协议，以在中东和北非（&#34;MENA 地区&#34;）商业化 FYB206，这是 Formycon 针对重磅药物 Keytruda®[1]（pembrolizumab）的生物仿制药候选药物。该协议包括未来技术转让的选项。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>Formycon 标志</p>
<p>&#34;这项针对 MENA 地区的许可协议标志着我们 Keytruda® 生物仿制药候选药物商业合作活动的开始。未来还将有针对其他地区和国家的进一步协议。与 MS Pharma 的合作，我们正在利用已经成功实施的 FYB201、FYB202 和 FYB203 生物仿制药的良好合作关系。MS Pharma 是一个强大的参与者，能够可持续地改善 MENA 地区对这一重要癌症药物的获取。FYB206 目前接近临床开发阶段的结束，我们预计将在 2026 年第一季度获得主要终点的结果，&#34; <strong>Formycon AG 的首席商务官 Nicola Mikulcik 说道。</strong></p>
<p>&#34;与 Formycon 扩大 FYB206（pembrolizumab）的合作关系，是 MS Pharma 一个战略性的重要里程碑。这一合作不仅巩固了我们在 MENA 地区生物仿制药领域的领导地位，还展示了我们扩大创新癌症疗法获取的承诺。利用 Formycon 的科学专长与我们在当地的成熟能力以及我们在沙特阿拉伯的先进制造设施，我们有能力提供满足 MENA 地区患者和医疗系统需求的高质量生物仿制药，&#34; <strong>MS Pharma 的首席执行官 Kalle Känd 评论道。</strong></p>
<p>在协议签署后，Formycon 将获得一次性报酬，并有资格获得基于某些开发和监管里程碑达成情况的进一步付款，Formycon 还将获得该地区产生的毛利润的显著份额。</p>
<p>MS Pharma 将继续为更大的治疗可及性做出贡献，同时支持专注于本地化、韧性和可持续获取肿瘤护理的国家战略。这一合作强化了 MS Pharma 作为该地区政府和医疗机构长期合作伙伴的角色，帮助维持患者的连续性和护理质量。</p>
<p>Pembrolizumab 是一种人源化单克隆抗体，属于免疫检查点抑制剂组，用于治疗多种肿瘤。凭借其在肿瘤学中的广泛适应症和 2024 年全球销售额达 295 亿美元 [2]，Keytruda® 目前是全球最畅销的药物之一。在 MENA 地区，预计销售额约为 2.4 亿美元 [3]，使其成为该地区销售最高的生物制剂，并突显出 MENA 地区对肿瘤学的巨大需求和市场潜力。</p>
<p><em>1.</em> <em>Keytruda® 是 Merck Sharp \u0026 Dohme LLC 的注册商标，该公司是 Merck \u0026 Co, Inc, Rahway, NJ/USA 的子公司。</em> <em>2.</em> <em>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results – Merck.com.</em> <em>3.</em> <em>IQVIA 招标数据，截止至 2025 年 6 月。</em></p>
<p><strong>关于 Formycon：</strong></p>
<p>Formycon AG (FSE: FYB) 是一家领先的独立高质量生物仿制药开发公司，专注于生物制药药物的后续产品。该公司专注于眼科、免疫学、免疫肿瘤学和其他关键疾病领域的治疗，覆盖从技术开发到临床试验再到监管机构批准的几乎整个价值链。为了商业化其生物仿制药，Formycon 依赖于全球范围内强大、值得信赖和长期的合作伙伴关系。Formycon 已经在市场上推出了两种生物仿制药 FYB201/ranibizumab 和 FYB202/ustekinumab。另一种生物仿制药 FYB203/aflibercept 已获得 FDA、EMA 和 MHRA 的批准。目前有四个管线候选药物，包括 FYB208/dupilumab，正在开发中。通过其生物仿制药，Formycon 正在为尽可能多的患者提供高效且可负担得起的药物做出重要贡献。</p>
<p>Formycon AG 总部位于慕尼黑，上市于法兰克福证券交易所的 Prime Standard：FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY，并且是 SDAX 选择指数的一部分。更多信息请访问：https://www.formycon.com。</p>
<p><strong>关于 MS Pharma：</strong></p>
<p>MS Pharma 是 MENA 地区领先的制药公司，专注于广泛的仿制药和生物制剂的开发、生产和分销。公司定位于快速增长，在约旦、阿尔及利亚和沙特阿拉伯运营五个制造设施，其中包括新近启动的生物制剂工厂，所有这些设施服务于更广泛的 MENA 市场。公司总部位于约旦安曼，在瑞士楚格设有管理办公室，MS Pharma 在 12 个国家雇佣超过 2000 名员工。有关更多信息，请访问：www.mspharma.com。</p>
<p><strong>关于生物仿制药：</strong></p>
<p>自 1980 年代引入以来，生物制药药物彻底改变了严重和慢性疾病的治疗。到 2032 年，许多这些药物将失去专利保护——包括 45 种年全球总营业额超过 2000 亿美元的重磅药物。生物类似药是生物制药药物的继任产品，其市场独占权已到期。它们在欧盟、美国、加拿大、日本和澳大利亚等高度监管的市场中，根据严格的监管程序获得批准。生物类似药创造了竞争，从而使更多患者能够获得生物制药疗法。同时，它们降低了医疗系统的成本。目前，生物类似药的全球销售额约为 210 亿美元。分析师预计，到 2030 年，销售额可能超过 740 亿美元。</p>
<p>Logo: https://mma.prnewswire.com/media/2759179/5655882/MS_Pharma_Logo.jpg</p>
<p>Logo: https://mma.prnewswire.com/media/2838456/Formycon_Logo.jpg</p>
<p><strong>联系方式：</strong> Sabrina Müller</p>
<p>投资者关系与企业传播总监</p>
<p>Formycon AG</p>
<p>Fraunhoferstr. 15</p>
<p>82152 Planegg-Martinsried</p>
<p>德国</p>
<p>电话：+49 (0) 89 - 86 46 67 149</p>
<p>传真：+ 49 (0) 89 - 86 46 67 110</p>
<p>[email protected]</p>
<p><strong>联系方式：</strong> Orayb Akeel</p>
<p>企业传播总监</p>
<p>MS Pharma</p>
<p>约旦安曼</p>
<p>电话：+962 (0) 77- 680 1114</p>
<p>[email protected]</p>
<p><strong>免责声明：</strong></p>
<p>本新闻稿可能包含基于 Formycon 当前预期和某些假设的前瞻性陈述和信息。各种已知和未知的风险、不确定性及其他因素可能导致实际未来结果、公司财务状况、业绩、产品发展与此处给出的估计之间存在重大差异。这些已知和未知的风险和不确定性包括但不限于研究与开发、监管批准过程、监管机构和其他政府当局的行动时机、临床结果、法律法规的变化、产品质量、患者安全、专利诉讼、合同风险以及对第三方的依赖。关于管线产品，Formycon AG 不提供任何陈述、保证或其他保证，确保产品将获得必要的监管批准或证明具有商业可行性和/或成功。Formycon AG 不承担更新这些前瞻性陈述或在发生与预期不同的发展时进行更正的义务。本文件既不构成出售的要约，也不构成购买或认购 Formycon AG 证券的要约邀请。Formycon AG 的证券不会进行公开发行，也不打算进行公开发行。本文件及其中包含的信息不得在美国、加拿大、澳大利亚、日本或任何其他禁止此类要约或邀请的司法管辖区内分发。该文件不构成在美国出售证券的要约。</p>
<p>来源 MS Pharma</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA0Jk5ld3NJdGVtSWQ9TE4zOTI5NSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDQwNDE0UFJfTkVXU19VU1BSX19fX19MTjM5Mjk1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA0Jk5ld3NJdGVtSWQ9TE4zOTI5NSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDQwNDE0UFJfTkVXU19VU1BSX19fX19MTjM5Mjk1"/></p>

<p>Formycon AG 和 MS Pharma 签署了一项独家许可和供应协议，以在中东和北非地区商业化 Formycon 的 Keytruda® 生物仿制药候选产品 FYB206。该协议包括未来的技术转让选项，旨在改善癌症治疗的可及性。Formycon 将获得预付款和毛利润分成，而 MS Pharma 将增强治疗的可用性并支持国家医疗保健战略</p>

<p>, /PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar candidate to the blockbuster drug Keytruda®[1] (pembrolizumab), in the Middle East and North Africa (&#34;MENA region&#34;). The agreement includes an option for future technology transfer.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) 和 MS Pharma 联合宣布，他们已签署一项独家许可和供应协议，以在中东和北非（&#34;MENA 地区&#34;）商业化 FYB206，这是 Formycon 针对重磅药物 Keytruda®[1]（pembrolizumab）的生物仿制药候选药物。该协议包括未来技术转让的选项。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Formycon Logo</p>
<div class="lb-trans"><p>Formycon 标志</p>
</div><p>&#34;This licensing deal for the MENA region represents the start of the commercial partnering activities for our Keytruda® biosimilar candidate. Further agreements for additional regions and countries shall follow in due time. With MS Pharma, we are leveraging the well-established excellent collaboration that has already been successfully implemented for our biosimilars FYB201, FYB202, and FYB203. MS Pharma is a strong player that can sustainably improve access to this important cancer drug across the MENA region. FYB206 is currently approaching the end of its clinical development phase, and we expect results for the primary endpoint in the first quarter of 2026,&#34; said <strong>Nicola Mikulcik, CBO of Formycon AG</strong>.</p>
<div class="lb-trans"><p>&#34;这项针对 MENA 地区的许可协议标志着我们 Keytruda® 生物仿制药候选药物商业合作活动的开始。未来还将有针对其他地区和国家的进一步协议。与 MS Pharma 的合作，我们正在利用已经成功实施的 FYB201、FYB202 和 FYB203 生物仿制药的良好合作关系。MS Pharma 是一个强大的参与者，能够可持续地改善 MENA 地区对这一重要癌症药物的获取。FYB206 目前接近临床开发阶段的结束，我们预计将在 2026 年第一季度获得主要终点的结果，&#34; <strong>Formycon AG 的首席商务官 Nicola Mikulcik 说道。</strong></p>
</div><p>&#34;Extending our partnership with Formycon for FYB206 (pembrolizumab), is a strategically important milestone for MS Pharma. This collaboration not only strengthens our position as a leader in biosimilars across the MENA region but also demonstrates our commitment to expanding access to innovative cancer therapies. Leveraging Formycon's scientific expertise with our established local capabilities and our advanced manufacturing facility in Saudi Arabia, we are well-positioned to deliver high-quality biosimilars that meet the needs of patients and healthcare systems in the MENA region,&#34; commented <strong>Kalle Känd, CEO of MS Pharma</strong>.</p>
<div class="lb-trans"><p>&#34;与 Formycon 扩大 FYB206（pembrolizumab）的合作关系，是 MS Pharma 一个战略性的重要里程碑。这一合作不仅巩固了我们在 MENA 地区生物仿制药领域的领导地位，还展示了我们扩大创新癌症疗法获取的承诺。利用 Formycon 的科学专长与我们在当地的成熟能力以及我们在沙特阿拉伯的先进制造设施，我们有能力提供满足 MENA 地区患者和医疗系统需求的高质量生物仿制药，&#34; <strong>MS Pharma 的首席执行官 Kalle Känd 评论道。</strong></p>
</div><p>Upon signature of the agreement, Formycon will receive an upfront remuneration and will be eligible for further payments contingent on the achievement of certain development and regulatory milestones, Formycon will further receive a significant share of the gross profits generated in the region.</p>
<div class="lb-trans"><p>在协议签署后，Formycon 将获得一次性报酬，并有资格获得基于某些开发和监管里程碑达成情况的进一步付款，Formycon 还将获得该地区产生的毛利润的显著份额。</p>
</div><p>MS Pharma will continue to contribute to greater treatment availability while supporting national strategies focused on localization, resilience, and sustainable access to oncology care. This collaboration reinforces MS Pharma's role as a long-term partner to governments and healthcare institutions across the region, helping maintain continuity and quality of care for patients.</p>
<div class="lb-trans"><p>MS Pharma 将继续为更大的治疗可及性做出贡献，同时支持专注于本地化、韧性和可持续获取肿瘤护理的国家战略。这一合作强化了 MS Pharma 作为该地区政府和医疗机构长期合作伙伴的角色，帮助维持患者的连续性和护理质量。</p>
</div><p>Pembrolizumab is a humanized monoclonal antibody that belongs to the group of immune checkpoint inhibitors and is used to treat a variety of tumors. With its broad range of indications in oncology and global sales of US$ 29.5 billion in 2024[2], Keytruda® is currently one of the world's best-selling drugs. In the MENA region, estimated sales reached approximately US$ 240 million[3], positioning it as the highest-selling biologic in the region and underscoring the substantial oncology demand and market potential across MENA.</p>
<div class="lb-trans"><p>Pembrolizumab 是一种人源化单克隆抗体，属于免疫检查点抑制剂组，用于治疗多种肿瘤。凭借其在肿瘤学中的广泛适应症和 2024 年全球销售额达 295 亿美元 [2]，Keytruda® 目前是全球最畅销的药物之一。在 MENA 地区，预计销售额约为 2.4 亿美元 [3]，使其成为该地区销售最高的生物制剂，并突显出 MENA 地区对肿瘤学的巨大需求和市场潜力。</p>
</div><p><em>1.</em> <em>Keytruda® is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co, Inc, Rahway, NJ/USA.</em> <em>2.</em> <em>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results – Merck.com.</em> <em>3.</em> <em>IQVIA tender data, YTD June 2025.</em></p>
<div class="lb-trans"><p><em>1.</em> <em>Keytruda® 是 Merck Sharp \u0026 Dohme LLC 的注册商标，该公司是 Merck \u0026 Co, Inc, Rahway, NJ/USA 的子公司。</em> <em>2.</em> <em>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results – Merck.com.</em> <em>3.</em> <em>IQVIA 招标数据，截止至 2025 年 6 月。</em></p>
</div><p><strong>About Formycon:</strong></p>
<div class="lb-trans"><p><strong>关于 Formycon：</strong></p>
</div><p>Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates – including FYB208/dupilumab – are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.</p>
<div class="lb-trans"><p>Formycon AG (FSE: FYB) 是一家领先的独立高质量生物仿制药开发公司，专注于生物制药药物的后续产品。该公司专注于眼科、免疫学、免疫肿瘤学和其他关键疾病领域的治疗，覆盖从技术开发到临床试验再到监管机构批准的几乎整个价值链。为了商业化其生物仿制药，Formycon 依赖于全球范围内强大、值得信赖和长期的合作伙伴关系。Formycon 已经在市场上推出了两种生物仿制药 FYB201/ranibizumab 和 FYB202/ustekinumab。另一种生物仿制药 FYB203/aflibercept 已获得 FDA、EMA 和 MHRA 的批准。目前有四个管线候选药物，包括 FYB208/dupilumab，正在开发中。通过其生物仿制药，Formycon 正在为尽可能多的患者提供高效且可负担得起的药物做出重要贡献。</p>
</div><p>Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX selection index. Further information can be found at: https://www.formycon.com.</p>
<div class="lb-trans"><p>Formycon AG 总部位于慕尼黑，上市于法兰克福证券交易所的 Prime Standard：FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY，并且是 SDAX 选择指数的一部分。更多信息请访问：https://www.formycon.com。</p>
</div><p><strong>About MS Pharma:</strong></p>
<div class="lb-trans"><p><strong>关于 MS Pharma：</strong></p>
</div><p>MS Pharma is a leading regional pharmaceutical company in the MENA region, specializing in the development, production, and distribution of a broad portfolio of generic and biologic therapies. Positioned for rapid growth, the company operates five manufacturing facilities across Jordan, Algeria, and Saudi Arabia – home to a newly launched biologics plant, all serving the broader MENA market. Headquartered in Amman, Jordan, with management offices in Zug, Switzerland, MS Pharma employs over 2,000 people across 12 countries. For more information, please visit: www.mspharma.com.</p>
<div class="lb-trans"><p>MS Pharma 是 MENA 地区领先的制药公司，专注于广泛的仿制药和生物制剂的开发、生产和分销。公司定位于快速增长，在约旦、阿尔及利亚和沙特阿拉伯运营五个制造设施，其中包括新近启动的生物制剂工厂，所有这些设施服务于更广泛的 MENA 市场。公司总部位于约旦安曼，在瑞士楚格设有管理办公室，MS Pharma 在 12 个国家雇佣超过 2000 名员工。有关更多信息，请访问：www.mspharma.com。</p>
</div><p><strong>About Biosimilars:</strong></p>
<div class="lb-trans"><p><strong>关于生物仿制药：</strong></p>
</div><p>Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.</p>
<div class="lb-trans"><p>自 1980 年代引入以来，生物制药药物彻底改变了严重和慢性疾病的治疗。到 2032 年，许多这些药物将失去专利保护——包括 45 种年全球总营业额超过 2000 亿美元的重磅药物。生物类似药是生物制药药物的继任产品，其市场独占权已到期。它们在欧盟、美国、加拿大、日本和澳大利亚等高度监管的市场中，根据严格的监管程序获得批准。生物类似药创造了竞争，从而使更多患者能够获得生物制药疗法。同时，它们降低了医疗系统的成本。目前，生物类似药的全球销售额约为 210 亿美元。分析师预计，到 2030 年，销售额可能超过 740 亿美元。</p>
</div><p>Logo: https://mma.prnewswire.com/media/2759179/5655882/MS_Pharma_Logo.jpg</p>
<div class="lb-trans"><p>Logo: https://mma.prnewswire.com/media/2759179/5655882/MS_Pharma_Logo.jpg</p>
</div><p>Logo: https://mma.prnewswire.com/media/2838456/Formycon_Logo.jpg</p>
<div class="lb-trans"><p>Logo: https://mma.prnewswire.com/media/2838456/Formycon_Logo.jpg</p>
</div><p><strong>Contact:</strong> Sabrina Müller</p>
<div class="lb-trans"><p><strong>联系方式：</strong> Sabrina Müller</p>
</div><p>Director Investor Relations &amp; Corporate Communications</p>
<div class="lb-trans"><p>投资者关系与企业传播总监</p>
</div><p>Formycon AG</p>
<div class="lb-trans"><p>Formycon AG</p>
</div><p>Fraunhoferstr. 15</p>
<div class="lb-trans"><p>Fraunhoferstr. 15</p>
</div><p>82152 Planegg-Martinsried</p>
<div class="lb-trans"><p>82152 Planegg-Martinsried</p>
</div><p>Germany</p>
<div class="lb-trans"><p>德国</p>
</div><p>Tel.: +49 (0) 89 - 86 46 67 149</p>
<div class="lb-trans"><p>电话：+49 (0) 89 - 86 46 67 149</p>
</div><p>Fax: + 49 (0) 89 - 86 46 67 110</p>
<div class="lb-trans"><p>传真：+ 49 (0) 89 - 86 46 67 110</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p><strong>Contact:</strong> Orayb Akeel</p>
<div class="lb-trans"><p><strong>联系方式：</strong> Orayb Akeel</p>
</div><p>Corporate Communications Director</p>
<div class="lb-trans"><p>企业传播总监</p>
</div><p>MS Pharma</p>
<div class="lb-trans"><p>MS Pharma</p>
</div><p>Amman – Jordan</p>
<div class="lb-trans"><p>约旦安曼</p>
</div><p>Tel: +962 (0) 77- 680 1114</p>
<div class="lb-trans"><p>电话：+962 (0) 77- 680 1114</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p><strong>Disclaimer:</strong></p>
<div class="lb-trans"><p><strong>免责声明：</strong></p>
</div><p>This press release may contain forward-looking statements and information which are based on Formycon's current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.</p>
<div class="lb-trans"><p>本新闻稿可能包含基于 Formycon 当前预期和某些假设的前瞻性陈述和信息。各种已知和未知的风险、不确定性及其他因素可能导致实际未来结果、公司财务状况、业绩、产品发展与此处给出的估计之间存在重大差异。这些已知和未知的风险和不确定性包括但不限于研究与开发、监管批准过程、监管机构和其他政府当局的行动时机、临床结果、法律法规的变化、产品质量、患者安全、专利诉讼、合同风险以及对第三方的依赖。关于管线产品，Formycon AG 不提供任何陈述、保证或其他保证，确保产品将获得必要的监管批准或证明具有商业可行性和/或成功。Formycon AG 不承担更新这些前瞻性陈述或在发生与预期不同的发展时进行更正的义务。本文件既不构成出售的要约，也不构成购买或认购 Formycon AG 证券的要约邀请。Formycon AG 的证券不会进行公开发行，也不打算进行公开发行。本文件及其中包含的信息不得在美国、加拿大、澳大利亚、日本或任何其他禁止此类要约或邀请的司法管辖区内分发。该文件不构成在美国出售证券的要约。</p>
</div><p>SOURCE MS Pharma</p>
<div class="lb-trans"><p>来源 MS Pharma</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA0Jk5ld3NJdGVtSWQ9TE4zOTI5NSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDQwNDE0UFJfTkVXU19VU1BSX19fX19MTjM5Mjk1" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN39295&amp;Transmission_Id=202512040414PR_NEWS_USPR_____LN39295&amp;DateId=20251204"/></p>

Formycon 与 MS Pharma 签署了针对 MENA 地区的 Keytruda®生物类似药候选产品 FYB206 的独家商业化合作协议